Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: A phase i trial of combined induction therapy and bortezomib consolidation

Rupali Roy*, Andrew M. Evens, David Patton, Lillia Gallot, Annette Larson, Alfred Rademaker, Jeffrey Cilley, Stewart Spies, Daina Variakojis, Leo I. Gordon, Jane N. Winter

*Corresponding author for this work

Research output: Contribution to journalArticle

9 Scopus citations


Preclinical studies suggest that bortezomib, through inhibition of nuclear factor-κB (NF-κB) activation, may enhance the effects of radioimmunotherapy. This phase I trial was designed to determine the maximum tolerated dose (MTD) of weekly bortezomib induction combined with Y-90-ibritumomab tiuxetan followed at the time of count recovery by weekly bortezomib consolidation in patients with relapsed/refractory follicular or transformed non-Hodgkin lymphoma. Grade 3 or 4 toxicities were observed in eight of nine treated patients, and all but one of these toxicities were hematologic. One patient had grade 3 cardiotoxicity. A dose limiting toxicity (DLT) of grade 4 thrombocytopenia was observed in two of three patients treated with bortezomib at 1.6 mg/m2, resulting in a MTD of 1.3 mg/m2. The overall response rate was 89% (two complete response [CR], six partial response [PR], one stable disease [SD]), with a median progression-free survival of 6.5 months (range: 3-22.5+ months). A phase II trial at the MTD is under way to better define the toxicity and effectiveness of this regimen.

Original languageEnglish (US)
Pages (from-to)497-502
Number of pages6
JournalLeukemia and Lymphoma
Issue number3
StatePublished - Mar 1 2013



  • Bortezomib
  • Follicular lymphoma
  • Y-90-ibritumomab tiuxetan

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this